Trametinib: a MEK inhibitor for management of metastatic melanoma

This review presents the current data on the efficacy and safety of the selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in patients with metastatic BRAF V600-positive melanoma. The pharmacological, safety, and efficacy data come from the Phase I, II, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lugowska, Iwona, Koseła-Paterczyk, Hanna, Kozak, Katarzyna, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556032/
https://www.ncbi.nlm.nih.gov/pubmed/26347206
http://dx.doi.org/10.2147/OTT.S72951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556032/
https://www.ncbi.nlm.nih.gov/pubmed/26347206
http://dx.doi.org/10.2147/OTT.S72951

Ejemplares similares